Skip to main content

Table 3 Background characteristics of patients with total cohort, group A and group B

From: Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer

 

Total

Group A (non-metastatic group)

Group B (metastatic group)

Number of patients

167

42

125

Age (median)

64.0

65.0

63.0

Gender (%)

   

Male

124 (74.3)

29 (69.0)

95 (76.0)

Female

43 (15.7)

13 (31.0)

30 (24.0)

ECOG PS (%)

   

0

79 (47.3)

33 (78.6)

46 (36.8)

1

86 (51.5)

9 (21.4)

77 (61.6)

2

2 (1.2)

0 (0.0)

2 (1.6)

Histological type (%)

   

Intestinal type

60 (35.9)

10 (23.8)

50 (40.0)

Diffuse type

107 (64.1)

36 (76.2)

71 (60.0)

T-stage

   

T1

9 (5.4)

7 (16.7)

2 (1.6)

T2

34 (20.4)

9 (21.4)

25 (20.0)

T3

101 (60.5)

22 (52.4)

79 (63.2)

T4

23 (13.8)

4 (9.5)

19 (15.2)

N-stage

   

Nx

4 (2.4)

2 (4.8)

2 (1.6)

N0

22 (13.2)

12 (28.6)

10 (8.0)

N1

56 (33.5)

16 (38.1)

40 (32.0)

N2

53 (31.7)

9 (21.4)

44 (35.2)

N3

32 (19.2)

3 (19.2)

29 (23.2)

Metastatic lesion (%)

   

1

135* (80.8)

40* (95.2)

95 (76.0)

2

32 (19.2)

2 (4.8)

30 (24.0)

Metastatic site (%)

   

Lymph node

92* (55.1)

19* (45.2)

73 (58.4)

Liver

34 (20.3)

2** (4.8)

32 (25.6)

Lung

8 (4.8)

0 (0.0)

8 (6.4)

Peritoneal dissemination

43 (25.7)

3** (7.1)

40 (32.0)

Other

6 (3.6)

0 (0.0)

6 (4.8)

  1. Abbreviations: ECOG PS Eastern Cooperative Oncology Group performance status. Staging (TNM classification) is diagnosed by Japanese Classification of Gastric Carcinoma (The 13th Edition) , *including metastasis to regional lymph nodes. **resectable lesion.